According to the Zhitong Finance App, Innote (688253.SH) disclosed its performance forecast for the first quarter of 2024. The company expects to achieve revenue of RMB 257 million to RMB 285 million in the first quarter, an increase of 91.06% to 111.88% over the previous year. Net profit attributable to shareholders of listed companies was RMB 138 million to RMB 154 million, an increase of 156.42% to 186.15% over the previous year.

According to reports, the company maintained a good trend in market development in the first quarter of 2024, benefiting from factors such as the continuous advancement of the national hierarchical diagnosis and treatment system, the release of a number of respiratory related clinical practice guidelines and expert consensus, the increase in patients' awareness of early diagnosis and treatment, and the company's efforts to develop the market for grade hospitals and primary care.